Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
0.9800
-0.0100 (-1.01%)
Streaming Delayed Price
Updated: 2:46 PM EDT, Apr 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
32
33
Next >
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%
February 02, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%
February 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience: Charting a Path to Commercial Success
January 31, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023
January 27, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs
January 25, 2023
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor
January 23, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor
January 23, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
January 23, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Provides Strategic Update in Annual Shareholder Letter
January 17, 2023
Via
Investor Brand Network
Topics
Economy
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Provides Strategic Update in Annual Shareholder Letter
January 17, 2023
Via
CannabisNewsWire
Topics
Economy
Intellectual Property
Lexaria Releases Annual Letter from the CEO
January 13, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)
January 12, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)
January 12, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada
January 11, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients
January 09, 2023
Via
Investor Brand Network
Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands
January 04, 2023
Via
Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures 28th Patent in International Portfolio
December 29, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Receives First Granted Patent in Canada
December 29, 2022
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability in Pharmaceuticals
December 27, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study
December 21, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study
December 21, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
December 21, 2022
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study
December 20, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study
December 20, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria’s Human Oral Nicotine Study Begins Dosing
December 20, 2022
Via
ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Expected to Yield Notable Results in Diabetes Study
December 16, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study
December 15, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review
December 13, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure
December 08, 2022
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure
December 08, 2022
Via
CannabisNewsWire
Topics
Intellectual Property
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.